NDA 204677 · Lantheus
Neuraceq
Florbetaben F-18 · Intravenous · Radioactive Diagnostic Agent
NovelLast checked: Nov 20, 2026Latest source record: Jul 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Mar 19, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
30
1 Phase 3, 9 recruiting
FAERS reports
21
5 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 24, 2026.
NEURACEQ is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 2025 Supplement 24 · Efficacy LabelLetter
- Mar 19, 2014 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- NEURACEQ · FLORBETABEN F-18 1.4-135mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Florbetaben F-18" as an intervention, any sponsor and status, largest first.
- Head-to-Head Harmonization of Tau Tracers in Alzheimer's DiseaseActive, not recruiting
Tharick PascoalAcademic, hospital or other
NCT05361382 · 822 participants · Start Mar 2, 2022 · Primary completion May 31, 2027
Drug: 18F-Flortaucipir radiopharmaceutical; 18F-MK-6240 radiopharmaceutical and 1 more · For: Alzheimer Disease
Sites: Berkeley, California; San Francisco, California; Rochester, Minnesota · 9 sites in all
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisPivotal-lookingCompleted
Lantheus Germany GmbHIndustry
NCT05184088 · 244 participants · Start Jan 13, 2023 · Primary completion Apr 21, 2026
Drug: [18F]florbetaben · For: Cardiac Amyloidosis; AL Amyloidosis; ATTR Amyloidosis
Sites: Kansas City, Kansas; Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania · 14 sites in all
Lantheus Biosciences Ltd.Industry
NCT02681172 · 218 participants · Start Oct 2015 · Primary completion Sep 2016
Drug: Neuraceq (florbetaben 18F) · For: Alzheimer's Disease (AD)
Sites: Marseille, France
National Institute of Mental Health (NIMH)NIH
NCT04396873 · 184 participants (planned) · Start Aug 17, 2021 · Primary completion Apr 11, 2029
Drug: 11C-MC1; 11C-PS13 and 1 more · For: Parkinson's Disease; Dementia; Alzheimer's Disease and 2 more
Sites: Bethesda, Maryland
- A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07787169 · 179 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 2028
Drug: LY4405094; LY4405094 and 2 more · For: Alzheimer Disease; Amyloid; Plaque, Amyloid and 1 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
Adam BrickmanAcademic, hospital or other
NCT03706261 · 145 participants · Start Mar 22, 2019 · Primary completion Jul 14, 2023
Drug: 18F-MK-6240; 18F-Florbetaben · For: Alzheimer Disease
Sites: New York, New York
- Alzheimer's Disease Research Center (ADRC) PET Component StudyEnrolling by invitation
Patrick LaoAcademic, hospital or other
NCT07758660 · 120 participants (planned) · Start Aug 6, 2026 · Primary completion May 31, 2031
Drug: 18F-MK6240; 18F-Florbetaben (FBB) · For: Alzheimer Disease; Mild Cognitive Impairment (MCI); Dementia
Sites: New York, New York
- A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07843459 · 111 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 2028
Drug: LY4560736; LY4560736 and 2 more · For: Healthy Volunteers; Alzheimer Disease; Amyloid and 2 more
Sites: Anaheim, California; Irvine, California; Los Alamitos, California · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amyloid related imaging abnormality-oedema/effusion6
- burning sensation4
- injection site pain4
- asthenia3
- fatigue3
- infusion related reaction3
- discomfort2
- dizziness2
- dyspnoea2
- headache2
- hyperhidrosis2
- nausea2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2023 | 7 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 5 |
Recalls
1 FDA enforcement reports for this application.
Aug 22, 2023 · Class II · Terminated
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tau PET probes for Alzheimer's disease detection and their structural characterization.
Chinnathambi S, Malik S, Chandrashekar M · Adv Protein Chem Struct Biol 2025 · Systematic Review, Research Support, N.I.H., Extramural
Sponsor: Lantheus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.